Ceftiofur Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Ceftiofur Market Analysis
The Ceftiofur market studied was anticipated to grow with a CAGR of 5.6% during the forecast period.
COVID-19 has affected the ceftiofur market significantly. The supply chain was disrupted, leading to difficulty in moving animal products, such as meat, milk, and eggs to markets. However, to cater to the disrupted demand-supply chain, the Food and Agriculture Organization, in April 2020, published a new policy regarding the production of livestock and the supply chain of livestock products during the pandemic to ensure sufficient production of livestock. In May 2020, Animal Health Europe announced the European Commission adding veterinary medicines to the ''Communication for the Implementation of the Green Lanes under the Guidelines for Border Management Measures'', to protect health and ensure the availability of goods and essential services for the stable supply of safe, nutritious food and protection of pets during the pandemic. Therefore, the market studied was affected largely by lockdowns and restrictions.
The major factor attributing to the growth of the market is a rise in the death rate among swine and cattle around the world with reproductive tract infections, and skin and soft tissue infections.
Higher demand for ceftiofur antibiotics can be due to their approval for treatment of bacterial respiratory disease associated with various bacterium. These bacteria include Actinobacillus pleuropneumoniae and Streptococcus suis infections among swine, Mannheimia haemolytica, and Haemophilus Somnus among cattle. According to the United States Department of Agriculture's Animal and Plant Health Inspection Service article about National Veterinary Services Laboratories Foreign Animal Disease Diagnostic Laboratory (FADDL), updated in June 2021, several infectious foreign animal disease (FAD) agents are studied in the facility in New York. The Diagnostics Services section of the FADDL can diagnose more than thirty exotic animal diseases (including foot-and-mouth disease, classical swine fever, African swine fever, and other diseases listed by the World Organization for Animal Health) and can perform thousands of diagnostic tests each year. With the help of diagnostics in veterinary, more infectious diseases are being detected which is contributing to the market growth, as it will open new opportunities for treatment options for such diseases.
Ceftiofur Market Trends
This section covers the major market trends shaping the Ceftiofur Market according to our research experts:
Swine segment is Expected to Hold the Major Market Share in the Ceftiofur Market
The swine segment is expected to account for the largest market revenue share during the forecast period. This dominance is attributed to increased awareness about animal health and protein-rich foods for pet animals. Also, the increased revenue can be attributed to their higher consumption across the world. According to the statistics published by The National Pork Board for the year 2020, the World Per Capita Pork Consumption shares 41.3% of total meat consumption across the globe. Thus, increased demand for these antibiotics is expected to increase to maintain a healthy swine population. Furthermore, a rise in funding by government authorities and livestock producers for research activities is likely to create more opportunities that are fueling the growth of the segment.
Major companies in the market such as Zoetis provide Ceftiofur for swine. EXCEDE by Zoetis for Swine is the crystalline-free acid of ceftiofur, a broad-spectrum cephalosporin antibiotic active against Gram-positive and Gram-negative bacteria, including strains that produce -lactamases, is present in the ready-to-use preparation known as sterile suspension. Like other cephalosporins, ceftiofur suppresses the formation of cell walls in vitro, making it antibacterial.
The presence of ceftiofur from key companies and the rising population of swine are expected to propel the market growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to retain its significant market share, owing to factors, like rising pet adoption and increasing per capita animal healthcare expenditure. Additionally, the rise in the prevalence of various animal diseases and injuries is a major factor that fuels the market growth.
According to the 2021-2022 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 70% of United States households own a pet, which equates to 90.5 million homes, including 45.3 million cats and 69 million dogs. The same source also reported that annual expenditure on routine visits for dogs accounted for USD 242, whereas it was USD 178 for cats. According to the Animal Cancer Foundation, 65 million dogs and 32 million cats in the United States are diagnosed with cancer. Moreover, approximately 6 million new cancer diagnosed in pets every year. With increasing ownership of pets and livestock, US citizens become more considerate of the health of these animals. According to the American Pet Products Association, the expenditure on pets in the United States is also rising, which may propel market growth.
Thus, with increased awareness and expenditure on animal health, the market is expected to show significant growth in the future.
Ceftiofur Industry Overview
The ceftiofur market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are developing new products with lesser side effects and launching across the world. Some of the companies which are currently dominating the market are Hester Biosciences Limited., Hipra, Zoetis Inc., Merck & Co., Inc., (MSD Animal Health), and Ceva Sante Animale
Ceftiofur Market Leaders
-
Hipra
-
Zoetis Inc.
-
Merck & Co., Inc., (MSD Animal Health)
-
Ceva Sante Animale
-
Hester Biosciences Limited
*Disclaimer: Major Players sorted in no particular order
Ceftiofur Market News
- In April 2022, the Zoetis Foundation announced that it will distribute USD 4.9 million during its first round of 2022 grants, supporting 20 initiatives based in 19 countries to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals as well as relief efforts in Ukraine.
- In May 2020, Norbrook launched Cefenil RTU (ceftiofur hydrochloride), the first ready-to-use generic injectable to treat Metritis in lactating dairy cows.
Ceftiofur Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Bovine Respiratory Disease and Swine Bacterial Pneumonia
- 4.2.2 Favorable Initiatives by Government Authorities and Rising Awareness among Livestock Producers
-
4.3 Market Restraints
- 4.3.1 High Cost of Medication and Treatment Procedures
- 4.3.2 Higher Risk of Adverse Effects Associated with these Antibiotics
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD million)
-
5.1 Drug Type
- 5.1.1 Ceftiofur Sodium
- 5.1.2 Ceftiofur Hydrochloride
- 5.1.3 Ceftiofur Crystalline Free Acid
-
5.2 Animal Type
- 5.2.1 Cattle
- 5.2.2 Horse
- 5.2.3 Swine
- 5.2.4 Others
-
5.3 Application
- 5.3.1 Respiratory Infections
- 5.3.2 Urinary Tract Infections
- 5.3.3 Bovine Interdigital Necrobacillosis
- 5.3.4 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United states
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Hester Biosciences Limited
- 6.1.2 Hipra
- 6.1.3 Zoetis Inc.
- 6.1.4 Merck & Co., Inc., (MSD Animal Health)
- 6.1.5 Ceva Sante Animale
- 6.1.6 Norbrook
- 6.1.7 Laboratorios Over SRL.
- 6.1.8 Vetoquinol S.A.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCeftiofur Industry Segmentation
As per the scope of this report, Ceftiofur is a third generation cephalosporin antibiotic that act by anti bacterial activity by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall and inactivating them. It is approved for use in veterinary medicine. The Ceftiofur market is segmented by Drug Type (Ceftiofur Sodium, Ceftiofur Hydrochloride, Ceftiofur Crystalline Free Acid), Animal Type (Cattle, Horse, Swine, Others), Application (Respiratory Infections, Urinary Tract Infections, Bovine Interdigital Necrobacillosis, Others), Geography (North America, Europe, Asia-Pacific, Rest of the World). The report offers the value (in USD million) for the above segments.
| Drug Type | Ceftiofur Sodium | |
| Ceftiofur Hydrochloride | ||
| Ceftiofur Crystalline Free Acid | ||
| Animal Type | Cattle | |
| Horse | ||
| Swine | ||
| Others | ||
| Application | Respiratory Infections | |
| Urinary Tract Infections | ||
| Bovine Interdigital Necrobacillosis | ||
| Others | ||
| Geography | North America | United states |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Rest of the World |
Ceftiofur Market Research FAQs
What is the current Global Ceftiofur Market size?
The Global Ceftiofur Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Global Ceftiofur Market?
Hipra, Zoetis Inc., Merck & Co., Inc., (MSD Animal Health), Ceva Sante Animale and Hester Biosciences Limited are the major companies operating in the Global Ceftiofur Market.
Which is the fastest growing region in Global Ceftiofur Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Ceftiofur Market?
In 2024, the North America accounts for the largest market share in Global Ceftiofur Market.
What years does this Global Ceftiofur Market cover?
The report covers the Global Ceftiofur Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Ceftiofur Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Ceftiofur Industry Report
Statistics for the 2024 Global Ceftiofur market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Ceftiofur analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
